The Trump administration on April 8 abandoned its legal effort to cap indirect-cost reimbursements on NIH grants, according to STAT. The move ends a court battle that had threatened to sharply reduce the overhead payments universities receive to support federally funded research — funds that cover lab infrastructure, core facilities, and institutional spending that underpins sequencing instrument placements across the academic market.
The retreat comes against a more threatening backdrop. The White House's fiscal year 2027 budget request, submitted April 3, proposed a $5 billion cut to NIH and a 12% reduction across federal health agencies, STAT reported. Congress is widely expected to reject the proposed NIH cuts, but the proposal creates planning uncertainty for institutions deciding whether to commit to multi-year instrument purchases and core facility expansions.
The budget proposal is layered on top of policy restrictions already taking a measurable toll. NIH restrictions on foreign research partnerships have significantly impacted 25% of U.S. scientists, according to a national survey of NIH-funded researchers reported by STAT on March 27. The foreign subaward ban has forced labs to restructure or abandon international collaborations, with knock-on effects for multi-site genomics studies and cross-border biobank access. A separate survey published March 19 described widespread funding cutbacks and disruptions among NIH-funded researchers, with one respondent comparing the state of U.S. science to "the Titanic."
The Los Angeles Times reported that the budget cuts threaten the future of biomedical research and young scientists, while Inside Higher Ed described the NIH policies as holding researchers "hostage."
For sequencing vendors, the commercial stakes are direct. Budget uncertainty chills purchasing decisions even when Congress ultimately restores funding, because institutional procurement cycles typically require multi-quarter lead times. The foreign subaward ban separately threatens the large-cohort, multi-population studies that have driven demand for high-throughput sequencing and generated validation data for clinical genomics products.
The indirect-cost reversal removes one immediate threat: had the cap been imposed, universities would have faced pressure to cut core facilities and shared instrumentation. But the underlying budget trajectory remains uncertain, and the foreign collaboration restrictions are already baked into grant structures for the current funding cycle.